Calls
3
Kim Sun-hwa
Committee Member, Bio Analyst
Win Rate
100.0%
return
+9.8%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jul 20
$171900.00
+8.8%
Despite recent underperformance versus US biotech, Korean large-cap biopharma companies (Samsung Biologics, Celltrion, SK Biopharm) have strong R&D pipelines, BD capabilities, and global competitiveness. Q4 will bring major academic conferences and potential tech transfer deals that will re-rate these stocks. Current levels offer an attractive long-term entry point.
Pharma & Biotech
Long
Jul 20
$1355000.00
+9.8%
Despite recent underperformance versus US biotech, Korean large-cap biopharma companies (Samsung Biologics, Celltrion, SK Biopharm) have strong R&D pipelines, BD capabilities, and global competitiveness. Q4 will bring major academic conferences and potential tech transfer deals that will re-rate these stocks. Current levels offer an attractive long-term entry point.
Pharma & Biotech
Long
Jul 20
$78000.00
+10.8%
Despite recent underperformance versus US biotech, Korean large-cap biopharma companies (Samsung Biologics, Celltrion, SK Biopharm) have strong R&D pipelines, BD capabilities, and global competitiveness. Q4 will bring major academic conferences and potential tech transfer deals that will re-rate these stocks. Current levels offer an attractive long-term entry point.
Pharma & Biotech
Showing 3 of 3 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Kim Sun-hwa has 3 trade ideas tracked on Buzzberg across 3 tickers since July 2026. Most covered: 068270.KS, 207940.KS, 326030.KS.
